Education
About Us
Working with TipRanks
Follow Us
CryoPort Inc (CYRX)
NASDAQ:CYRX
Top Page
CryoPort
(NASDAQ:CYRX)
49Neutral
Positive Factors
Business Growth
Commercial revenue increased by 37% year over year, and the number of commercial therapies increased from 14 to 19, showing signs of growth in the business.
Financial Performance
Total revenue exceeded consensus estimates, indicating stronger-than-expected performance.
Negative Factors
Market Uncertainty
Significant uncertainty remains in the healthcare market due to tariffs, China tensions, and turnover at FDA and NIH, which could drive downside risks.
CryoPort (CYRX) vs. S&P 500 (SPY)
Market Cap
$331.90M
Dividend YieldN/A
Average Volume (3M)403.16K
Price to Earnings (P/E)―
Beta (1Y)1.62
Revenue Growth-2.09%
EPS Growth-13.01%
CountryUS
Employees1,170
SectorIndustrials
Sector Strength72
IndustryTransportation
Share Statistics
EPS (TTM)-2.49
Shares Outstanding49,910,393
10 Day Avg. Volume756,716
30 Day Avg. Volume403,156
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.03
Price to Cash Flow (P/CF)-10.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.42Price Target Upside71.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
CryoPort Business Overview & Revenue Model
Company DescriptionCryoPort, Inc. (CYRX) is a leading provider of temperature-controlled logistics solutions to the life sciences industry. The company specializes in the transport of sensitive biological materials, including cell and gene therapies, vaccines, and other high-value commodities, ensuring that they are stored and delivered under strict temperature conditions. CryoPort's services are crucial for clinical trials, biopharmaceuticals, and reproductive medicine sectors, offering a comprehensive suite of logistics solutions that ensure the integrity and security of biological specimens throughout the supply chain.
How the Company Makes MoneyCryoPort generates revenue primarily through its temperature-controlled logistics services, which are offered to clients in the life sciences industry. Key revenue streams include transportation and logistics services for cell and gene therapy companies, biopharmaceutical companies, and research organizations. These services are supported by CryoPort's proprietary Cryoport Express® Shippers, Cryoport Certified™ Logistics Centers, and advanced monitoring systems that ensure the safe and secure shipment of temperature-sensitive materials. The company also benefits from long-term partnerships and contracts with leading biopharmaceutical companies and research institutions, which provide a stable and recurring revenue base. Additionally, CryoPort's acquisitions in the logistics and supply chain sectors have expanded its service portfolio, contributing to its overall earnings.
CryoPort Financial Statement Overview
Summary
CryoPort faces significant financial challenges with declining revenues, persistent losses, and strained cash flow. While the balance sheet shows some stability in leverage, the company struggles with profitability and liquidity, potentially impacting its ability to sustain operations without strategic changes or external support.Income Statement
CryoPort has experienced declining revenues with a 2% decrease from 2023 to 2024. The company faces significant profitability challenges, with a negative net profit margin of -53.7% and negative EBIT and EBITDA margins, indicating operational inefficiencies. The consistent decline in gross profit margin, standing at 43.6% for 2024, further reflects pressure on maintaining profitability.45
Neutral
Balance Sheet
The balance sheet shows a moderate level of financial stability, with a debt-to-equity ratio of 0.62, indicating a manageable level of leverage. However, the return on equity remains negative, reflecting ongoing net losses. The equity ratio is 57.1%, suggesting a reasonable proportion of equity financing. Overall, the balance sheet exhibits a stable but strained financial position.50
Neutral
Cash Flow
Cash flow analysis reveals negative free cash flow, highlighting liquidity challenges. Although operating cash flow has worsened from -$0.76 million in 2023 to -$16.3 million in 2024, the free cash flow to net income ratio remains negative. The negative operating cash flow to net income ratio also underscores ongoing operational cash burn.40
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 226.11M | 228.38M | 233.25M | 237.28M | 222.61M | 78.70M | Gross Profit |
| 86.72M | 99.63M | 99.33M | 103.87M | 96.58M | 36.33M | EBIT |
| -72.31M | -130.87M | -115.16M | -31.90M | -17.83M | -30.01M | EBITDA |
| -123.49M | -130.87M | -66.36M | -6.19M | -248.91M | -20.31M | Net Income Common Stockholders |
| -158.47M | -122.76M | -99.59M | -37.33M | -275.53M | -32.69M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 47.26M | 261.75M | 456.75M | 523.32M | 628.80M | 93.32M | Total Assets |
| 56.62M | 703.49M | 957.74M | 1.04B | 1.11B | 552.40M | Total Debt |
| 14.77M | 250.70M | 416.00M | 435.91M | 427.06M | 130.92M | Net Debt |
| -22.56M | 205.41M | 369.66M | 399.31M | 287.95M | 94.05M | Total Liabilities |
| 18.07M | 301.59M | 468.72M | 482.91M | 471.14M | 169.71M | Stockholders Equity |
| 38.55M | 401.90M | 489.02M | 555.84M | 641.83M | 382.70M |
| Cash Flow | Free Cash Flow | ||||
| -32.64M | -33.58M | -45.66M | -26.05M | -16.88M | -24.54M | Operating Cash Flow |
| -8.36M | -16.32M | -757.00K | -1.85M | 8.13M | -14.87M | Investing Cash Flow |
| 158.58M | 176.81M | 36.05M | -59.68M | -469.25M | -382.31M | Financing Cash Flow |
| -163.67M | -161.53M | -23.80M | -39.17M | 564.34M | 385.58M |
CryoPort Technical Analysis
Negative
6.65
Price Trends
7.18
Negative
7.30
Negative
7.92
Negative
Market Momentum
-0.36
Negative
51.83
Neutral
59.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYRX, the sentiment is Negative. The current price of 6.65 is above the 20-day moving average (MA) of 6.18, below the 50-day MA of 7.18, and below the 200-day MA of 7.92, indicating a neutral trend. The MACD of -0.36 indicates Negative momentum. The RSI at 51.83 is Neutral, neither overbought nor oversold. The STOCH value of 59.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CYRX.
CryoPort Risk Analysis
CryoPort disclosed 33 risk factors in its most recent earnings report. CryoPort reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CryoPort Peers Comparison
Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $14.20B | 18.43 | 8.44% | ― | 1.99% | 28.86% | |
69 Neutral | $9.77B | 42.25 | 19.71% | ― | 52.97% | ― | |
68 Neutral | $3.80B | ― | -3.53% | 4.02% | -6.05% | -1677.05% | |
62 Neutral | $8.16B | 12.85 | 0.64% | 3.04% | 3.83% | -15.83% | |
61 Neutral | $8.52B | 649.63 | 0.45% | ― | -1.92% | -96.95% | |
55 Neutral | $1.25B | ― | -6.14% | ― | -20.89% | 83.44% | |
49 Neutral | $331.90M | ― | -25.76% | ― | -2.09% | -13.01% |
* Industrials Sector Average
Performance Comparison
CYRX
CryoPort
6.65
-7.71
-53.69%
CRL
Charles River Labs
166.63
-94.55
-36.20%
ICLR
Icon
175.78
-157.72
-47.29%
PRGO
Perrigo Company
27.88
-1.94
-6.51%
SRPT
Sarepta Therapeutics
100.71
-21.25
-17.42%
BLFS
BioLife Solutions
26.62
9.01
51.16%
CryoPort Earnings Call Summary
Earnings Call Date: Mar 4, 2025 | % Change Since: 31.42% | Next Earnings Date: May 1, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong revenue performance, particularly in the Life Sciences Services business and commercial revenue growth. The company achieved significant improvements in gross margin and is optimistic about future revenue growth and profitability in 2025. However, macroeconomic challenges and concerns over the China market were noted as lowlights.Highlights
Solid Revenue Performance
Cryoport concluded the year with total annual revenues of $228.4 million, in line with expectations. The Life Sciences Services business saw double-digit year-over-year growth in BioStorage and BioServices revenue for both the fourth quarter and full year.
Commercial Revenue Growth
Revenue growth for the support of commercial cell and gene therapies increased by 37% in the fourth quarter and 20% for the full year.
Expansion in Clinical Trials
Cryoport supported 701 clinical trials by the end of the year, a net increase of 26 clinical trials from the previous year, with a record number of commercial approvals increasing from 14 to 19.
Gross Margin Improvement
Gross margin rose to 45.8% in the fourth quarter compared to 40.6% in the same period last year due to cost management initiatives.
IntegriCell and New Product Launch
Opened IntegriCell cryopreservation solution facilities in Houston, Texas and Liege, Belgium. Introduced the Cryoport Express Cryogenic CXHV3 shipping system.
Positive Outlook for 2025
Providing full-year 2025 revenue guidance in the range of $240 million to $250 million, with an expectation of achieving positive adjusted EBITDA during 2025.
Lowlights
Macroeconomic Challenges
2024 was a tough year for life sciences due to macroeconomic conditions and market dynamics.
China Market Concerns
Concerns over Chinese retaliations on tariffs, though currently China represents less than 3% of total revenue.
Company Guidance
In Cryoport's Fourth Quarter and Full Year 2024 Earnings Conference Call, the company reported annual revenues of $228.4 million, aligning with expectations despite a challenging year for the life sciences sector. The Life Sciences Services segment, which accounted for 67% of total revenue, experienced double-digit growth in BioStorage and BioServices, with commercial cell and gene therapy support revenues increasing by 37% in Q4 and 20% for the full year. The company supported 701 clinical trials by year-end, a net increase of 26 from the previous year, with 81 trials in Phase 3. Cryoport's gross margin improved significantly, rising to 45.8% in Q4 from 40.6% the previous year, driven by cost management initiatives. Looking ahead to 2025, Cryoport provided revenue guidance between $240 million and $250 million, anticipating further capitalizing on cell and gene therapy industry growth and achieving positive adjusted EBITDA.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.